ADTL-SA1215

ADTL-SA1215
Clinical data
Drug classSirtuin-3 (SIRT3) activator
Identifiers
  • (2-butyl-1-benzofuran-3-yl)-[3,5-diiodo-4-(3-pyrrolidin-1-ylpropoxy)phenyl]methanone
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H29I2N2O3
Molar mass671.338 g·mol−1
3D model (JSmol)
  • CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCCN4CCCC4)I
  • InChI=1S/C26H29I2NO3/c1-2-3-10-23-24(19-9-4-5-11-22(19)32-23)25(30)18-16-20(27)26(21(28)17-18)31-15-8-14-29-12-6-7-13-29/h4-5,9,11,16-17H,2-3,6-8,10,12-15H2,1H3
  • Key:NKCYHTOLLMRNJO-UHFFFAOYSA-N

ADTL-SA1215 is a drug which acts as a sirtuin-3 (SIRT3) activator. It has been researched as a potential therapeutic agent for the treatment of triple negative breast cancer, as well as being used for basic research into the structure and function of the SIRT3 enzyme complex.[1][2]

References

[edit]
  1. ^ Zhang J, Zou L, Shi D, Liu J, Zhang J, Zhao R, et al. (October 2021). "Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer". Journal of Medicinal Chemistry. 64 (19): 14192–14216. doi:10.1021/acs.jmedchem.0c02268. PMID 34605238.
  2. ^ Bursch KL, Goetz CJ, Smith BC (March 2024). "Current Trends in Sirtuin Activator and Inhibitor Development". Molecules. 29 (5): 1185. doi:10.3390/molecules29051185. PMC 10934002. PMID 38474697.